がん支持療法薬の世界市場レポート 2025年

がん支持療法薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.5％で261億米ドルに成長します。予測期間の成長は、がん治療の副作用に関する意識の高まり、女性の乳がん患者の増加、特定の投薬計画の利用可能性、オンライン診察の需要、医薬品部門のサプライチェーンの改善、がんサバイバー人口の増加などに起因すると考えられます。予測期間における主な動向としては、標的治療の進歩、生物行動学的介入の統合、サバイバーシップケアプランの実施、栄養サポートの統合、疼痛管理戦略の進歩、症状モニタリングプラットフォームの実施などが挙げられます。

がん患者の生存率の向上は、がん支持療法薬市場の今後の成長を促進すると予測されます。がん生存率とは、特定の種類のがんと診断された後、指定された期間（通常は5年間）生存する個人の割合を指します。この生存率は、主に早期発見、治療の進歩、質の高いヘルスケアへのアクセス、患者の全体的な健康状態、がんの種類とステージ、社会経済的要因の影響を受ける。がん支持療法薬は、疼痛、吐き気、貧血などの副作用を管理することで、患者が治療に耐えられるようにし、治療期間を全うできるようにすることで、生存率を向上させるという重要な役割を担っています。例えば、2022年1月現在、米国の政府機関である国立がん研究所は、今後10年間でがん生存者数が24.4％増加し、2032年には2,250万人に達すると予測しています。このように、がん患者の生存率の向上ががん支持療法薬市場の成長を後押ししています。

がん支持療法薬市場の主要企業は、がん治療の複雑さと課題に対処するために併用療法を開発しています。併用療法は、2種類以上の治療薬を戦略的に使用し、がんの増殖と生存の異なる側面を標的とすることで、単剤療法と比較してより深く持続的な奏効を目指すものです。例えば、米国の製薬会社メルク社は2023年11月、抗PD-1療法であるKEYTRUDAとゲムシタビンおよびシスプラチンの併用療法について、局所進行切除不能または転移性の胆道がん（BTC）患者の治療薬として、米国の連邦機関である食品医薬品局から承認を取得しました。この併用療法は、全生存期間の改善において有望な結果を示し、この課題のある胆道がん患者に新たな治療選択肢を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界がん支持療法薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のがん支持療法薬市場：成長率分析
• 世界のがん支持療法薬市場の実績：規模と成長, 2019-2024
• 世界のがん支持療法薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界がん支持療法薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがん支持療法薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 赤血球造血刺激因子
• 顆粒球コロニー刺激因子
• 制吐剤
• ビスホスホネート
• オピオイド
• 非ステロイド性抗炎症薬
• その他のタイプ
• 世界のがん支持療法薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 肺がん
• 大腸がん
• 前立腺がん
• 肝臓がん
• 胃がん
• その他の用途
• 世界のがん支持療法薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 専門クリニック
• その他のチャンネル
• 世界のがん支持療法薬市場赤血球造血刺激因子製剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エポエチンアルファ
• ダルベポエチンアルファ
• メトキシポリエチレングリコール-エポエチンベータ
• 世界のがん支持療法薬市場顆粒球コロニー刺激因子の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フィルグラスチム
• ペグフィルグラスチム
• レノグラスチム
• 世界のがん支持療法薬市場制吐剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 5-HT3受容体拮抗薬
• NK1受容体拮抗薬
• コルチコステロイド
• 世界のがん支持療法薬市場ビスホスホネートの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゾレドロン酸
• パミドロン酸
• イバンドロネート
• 世界のがん支持療法薬市場オピオイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モルヒネ
• フェンタニル
• オキシコドン
• 世界のがん支持療法薬市場非ステロイド性抗炎症薬（NSAID）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イブプロフェン
• ジクロフェナク
• セレコキシブ
• 世界のがん支持療法薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ステロイド
• 抗不安薬
• 食欲増進剤

第7章 地域別・国別分析

• 世界のがん支持療法薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のがん支持療法薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん支持療法薬市場：競合情勢
• がん支持療法薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• F Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Baxter International Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Incyte Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がん支持療法薬市場2029：新たな機会を提供する国
• がん支持療法薬市場2029：新たな機会を提供するセグメント
• がん支持療法薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Supportive care drugs for cancer play a crucial role in managing the adverse effects and symptoms associated with cancer treatments, significantly enhancing the quality of life for patients. These medications effectively address issues such as pain, nausea, anemia, and psychological stress, enabling patients to better tolerate their cancer therapies. By offering comprehensive symptom relief, supportive care drugs empower patients to maintain their strength and well-being throughout their treatment journey.

The primary categories of cancer supportive care drugs include erythropoiesis stimulating agents, granulocyte colony stimulating factors, antiemetics, bisphosphonates, opioids, nonsteroidal anti-inflammatory drugs, and others. Erythropoiesis-stimulating agents (ESAs) are a specific class of drugs designed to stimulate the production of red blood cells (erythropoiesis) in the bone marrow. These drugs find applications in various cancer types such as breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, among others, and are distributed through various channels including hospital pharmacies, retail pharmacies, online pharmacies, specialty clinics, and others.

The cancer supportive care drugs market research report is one of a series of new reports from The Business Research Company that provides cancer supportive care drugs market statistics, including cancer supportive care drugs industry global market size, regional shares, competitors with a cancer supportive care drugs market share, detailed cancer supportive care drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cancer supportive care drugs industry. This cancer supportive care drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer supportive care drugs market size has grown steadily in recent years. It will grow from $20.83 billion in 2024 to $21.85 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to rising geriatric population, increasing prevalence of chemotherapy, growing demand for antiemetics, growing preference for online pharmacies and drug stores, increasing awareness of supportive care, increasing adoption of personalized medicine, growing emphasis on palliative care.

The cancer supportive care drugs market size is expected to see steady growth in the next few years. It will grow to $26.1 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to rising awareness about adverse effects of cancer treatment, growing cases of breast cancer among females, the availability of specific medication plans, demand for online doctor consultations, an improved supply chain in the pharmaceutical sector, increasing the population of cancer survivors. Major trends in the forecast period include advancements in targeted therapies, integration of biobehavioral interventions, implementation of survivorship care plans, integration of nutritional support, advancements in pain management strategies, implementation of symptom monitoring platforms.

The improved survival rate for cancer patients is anticipated to drive the growth of the cancer supportive care drugs market moving forward. The cancer survival rate refers to the percentage of individuals who survive a specific type of cancer for a designated period, typically five years, after diagnosis. These survival rates are primarily influenced by early detection, advances in treatment, access to quality healthcare, the patient's overall health, the type and stage of cancer, and socioeconomic factors. Cancer supportive care drugs play a crucial role in enhancing survival rates by managing side effects such as pain, nausea, and anemia, enabling patients to better tolerate their treatments and complete their full course of therapy, which can lead to improved outcomes. For example, as of January 2022, the National Cancer Institute, a US-based government agency, projects a 24.4% increase in the number of cancer survivors over the next ten years, reaching 22.5 million by 2032. Thus, the improved survival rate of cancer patients is fueling the growth of the cancer supportive care drugs market.

Major companies in the cancer supportive care drugs market are developing combination therapies to address the complexity and challenges of cancer treatment. Combination therapies strategically use two or more therapeutic agents to target different aspects of cancer growth and survival, aiming to achieve deeper and more durable responses compared to monotherapy. For instance, in November 2023, Merck, a US-based pharmaceutical company, received approval from the Food and Drug Administration, a US-based federal agency, for KEYTRUDA, an anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for treating patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). The combination therapy showed promising results in improving overall survival and providing a new treatment option for patients with this challenging condition.

In March 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Ambrx Biopharma Inc. for $2 billion. The acquisition enhances Johnson & Johnson's capabilities in the design and development of targeted oncology therapeutics, particularly in cancer supportive care drugs. This strategic move underscores Johnson & Johnson's commitment to expanding its oncology portfolio, especially in prostate cancer research, and strengthening its capabilities in developing next-generation antibody-drug conjugates (ADCs). Ambrx Biopharma Inc. is a US-based biotechnology company that develops cancer supportive care drugs, including next-generation ADCs.

Major companies operating in the cancer supportive care drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, F Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Incyte Corporation, Exelixis Inc, Fagron Group, Heron Therapeutics Inc., Athenex Inc., Acrotech Biopharma LLC

North America was the largest region in the cancer supportive care drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer supportive care drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cancer supportive care drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cancer supportive care drugs market consists of the sale of analgesics, hematopoietic growth factors, bone modifying agents, corticosteroids, appetite stimulants, anti-diarrheal and laxatives, anti-anxiety and antidepressant medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Supportive Care Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer supportive care drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer supportive care drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer supportive care drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Erythropoiesis Stimulating Agents; Granulocyte Colony Stimulating Factors; Antiemetics; Bisphosphonates; Opioids; Nonsteroidal Anti Inflammatory Drugs; Other Types
• 2) By Application: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Liver Cancer; Stomach Cancer; Other Applications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics; Other Channels
• Subsegments:
• 1) By Erythropoiesis Stimulating Agents: Epoetin Alfa; Darbepoetin Alfa; Methoxy Polyethylene Glycol-Epoetin Beta
• 2) By Granulocyte Colony Stimulating Factors: Filgrastim; Pegfilgrastim; Lenograstim
• 3) By Antiemetics: 5-HT3 Receptor Antagonists; NK1 Receptor Antagonists; Corticosteroids
• 4) By Bisphosphonates: Zoledronic Acid; Pamidronate; Ibandronate
• 5) By Opioids: Morphine; Fentanyl; Oxycodone
• 6) By Nonsteroidal Anti Inflammatory Drugs (NSAIDs): Ibuprofen; Diclofenac; Celecoxib
• 7) By Other Types: Steroids; Anxiolytics; Appetite Stimulants
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Supportive Care Drugs Market Characteristics

3. Cancer Supportive Care Drugs Market Trends And Strategies

4. Cancer Supportive Care Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cancer Supportive Care Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cancer Supportive Care Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cancer Supportive Care Drugs Market Growth Rate Analysis
• 5.4. Global Cancer Supportive Care Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cancer Supportive Care Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cancer Supportive Care Drugs Total Addressable Market (TAM)

6. Cancer Supportive Care Drugs Market Segmentation

• 6.1. Global Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erythropoiesis Stimulating Agents
• Granulocyte Colony Stimulating Factors
• Antiemetics
• Bisphosphonates
• Opioids
• Nonsteroidal Anti Inflammatory Drugs
• Other Types
• 6.2. Global Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Stomach Cancer
• Other Applications
• 6.3. Global Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• Other Channels
• 6.4. Global Cancer Supportive Care Drugs Market, Sub-Segmentation Of Erythropoiesis Stimulating Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epoetin Alfa
• Darbepoetin Alfa
• Methoxy Polyethylene Glycol-Epoetin Beta
• 6.5. Global Cancer Supportive Care Drugs Market, Sub-Segmentation Of Granulocyte Colony Stimulating Factors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Filgrastim
• Pegfilgrastim
• Lenograstim
• 6.6. Global Cancer Supportive Care Drugs Market, Sub-Segmentation Of Antiemetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 5-HT3 Receptor Antagonists
• NK1 Receptor Antagonists
• Corticosteroids
• 6.7. Global Cancer Supportive Care Drugs Market, Sub-Segmentation Of Bisphosphonates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zoledronic Acid
• Pamidronate
• Ibandronate
• 6.8. Global Cancer Supportive Care Drugs Market, Sub-Segmentation Of Opioids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Morphine
• Fentanyl
• Oxycodone
• 6.9. Global Cancer Supportive Care Drugs Market, Sub-Segmentation Of Nonsteroidal Anti Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Diclofenac
• Celecoxib
• 6.10. Global Cancer Supportive Care Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Steroids
• Anxiolytics
• Appetite Stimulants

7. Cancer Supportive Care Drugs Market Regional And Country Analysis

• 7.1. Global Cancer Supportive Care Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cancer Supportive Care Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Supportive Care Drugs Market

• 8.1. Asia-Pacific Cancer Supportive Care Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Supportive Care Drugs Market

• 9.1. China Cancer Supportive Care Drugs Market Overview
• 9.2. China Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Supportive Care Drugs Market

• 10.1. India Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Supportive Care Drugs Market

• 11.1. Japan Cancer Supportive Care Drugs Market Overview
• 11.2. Japan Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Supportive Care Drugs Market

• 12.1. Australia Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Supportive Care Drugs Market

• 13.1. Indonesia Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Supportive Care Drugs Market

• 14.1. South Korea Cancer Supportive Care Drugs Market Overview
• 14.2. South Korea Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Supportive Care Drugs Market

• 15.1. Western Europe Cancer Supportive Care Drugs Market Overview
• 15.2. Western Europe Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Supportive Care Drugs Market

• 16.1. UK Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Supportive Care Drugs Market

• 17.1. Germany Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Supportive Care Drugs Market

• 18.1. France Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Supportive Care Drugs Market

• 19.1. Italy Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Supportive Care Drugs Market

• 20.1. Spain Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Supportive Care Drugs Market

• 21.1. Eastern Europe Cancer Supportive Care Drugs Market Overview
• 21.2. Eastern Europe Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Supportive Care Drugs Market

• 22.1. Russia Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Supportive Care Drugs Market

• 23.1. North America Cancer Supportive Care Drugs Market Overview
• 23.2. North America Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Supportive Care Drugs Market

• 24.1. USA Cancer Supportive Care Drugs Market Overview
• 24.2. USA Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Supportive Care Drugs Market

• 25.1. Canada Cancer Supportive Care Drugs Market Overview
• 25.2. Canada Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Supportive Care Drugs Market

• 26.1. South America Cancer Supportive Care Drugs Market Overview
• 26.2. South America Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Supportive Care Drugs Market

• 27.1. Brazil Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Supportive Care Drugs Market

• 28.1. Middle East Cancer Supportive Care Drugs Market Overview
• 28.2. Middle East Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Supportive Care Drugs Market

• 29.1. Africa Cancer Supportive Care Drugs Market Overview
• 29.2. Africa Cancer Supportive Care Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cancer Supportive Care Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cancer Supportive Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Supportive Care Drugs Market Competitive Landscape And Company Profiles

• 30.1. Cancer Supportive Care Drugs Market Competitive Landscape
• 30.2. Cancer Supportive Care Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Supportive Care Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Novartis AG
• 31.5. F Hoffmann-La Roche Ltd
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. GlaxoSmithKline plc
• 31.8. Eli Lilly and Company
• 31.9. Amgen Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Baxter International Inc.
• 31.12. Otsuka Pharmaceutical Co. Ltd.
• 31.13. Astellas Pharma Inc.
• 31.14. Eisai Co. Ltd.
• 31.15. Incyte Corporation

32. Global Cancer Supportive Care Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Supportive Care Drugs Market

34. Recent Developments In The Cancer Supportive Care Drugs Market

35. Cancer Supportive Care Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Cancer Supportive Care Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cancer Supportive Care Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cancer Supportive Care Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer